Piramal Pharma UK Facility Gets 7 US FDA Observations

1 Minute Read Listen to Article

Sep 14, 2026 22:09

Piramal Pharma's UK Morpeth facility received 7 observations from the US FDA after an inspection. The company is addressing the Form-483 findings.

Piramal Pharma UK Facility Gets 7 US FDA Observations

Photograph: Kind courtesy jorono/Pixabay.com

Key Points

Piramal Pharma's Morpeth facility in the UK received seven observations from the US FDA.
The US FDA conducted the inspection at the facility from September 3-11, 2026.
The observations, issued on a Form-483, relate to enhancements in practices, procedures, and documentation.
Piramal Pharma is preparing a detailed response to address these observations for the US FDA.
The company affirmed its commitment to maintaining high compliance standards and working with the agency.

New Delhi, Sep 14 (PTI) Piramal Pharma Limited's Morpeth facility in the UK has received seven observations after an inspection by the US Food and Drug Administration (US FDA), according to a regulatory filing.

The US FDA conducted the inspection at the facility from September 3-11, 2026, the company said in the filing.

"At the conclusion of the inspection, the USFDA issued a Form-483, with 7 observations. These observations are related to enhancement in our practices, procedures and documentation," Piramal Pharma stated.

The company said it is addressing these observations and preparing a detailed response for submission to the USFDA within the stipulated timeline.

Piramal Pharma added that it remains committed to maintaining the highest standards of compliance and will work closely with the agency to address all observations comprehensively.

Source: PTI By Rediff Money Desk, New Delhi

DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.